MDCX

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.21
Percentage change 2.97	%

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.43	Insider Own	77.42%	Shs Outstand	13.42M	Perf Week	8.32%
Market Cap	98.38M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-0.71%	Shs Float	2.67M	Perf Month	84.06%
Income	-14.47M	PEG	-	EPS next Q	-0.25	Inst Own	25.73%	Short Float	1.76%	Perf Quarter	91.34%
Sales	0.00M	P/S	-	EPS this Y	11.21%	Inst Trans	-	Short Ratio	0.43	Perf Half Y	248.80%
Book/sh	0.16	P/B	45.55	EPS next Y	6.47%	ROA	-435.53%	Short Interest	0.05M	Perf Year	-
Cash/sh	0.29	P/C	24.72	EPS next 5Y	5.68%	ROE	-1882.04%	52W Range	1.80 - 8.94	Perf YTD	200.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-623.03%	52W High	-18.46%	Beta	-
Dividend TTM	-	Quick Ratio	1.53	Sales past 5Y	0.00%	Gross Margin	-	52W Low	305.00%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	1.53	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	70.96	Volatility	5.06% 6.64%
Employees	12	Debt/Eq	0.13	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	19.67
Option/Short	No / Yes	LT Debt/Eq	0.08	EPS Q/Q	-87.92%	Payout	-	Rel Volume	1.30	Prev Close	7.08
Sales Surprise	-	EPS Surprise	-70.25%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	109.45K	Price	7.29
SMA20	33.32%	SMA50	68.54%	SMA200	106.92%	Trades		Volume	142,644	Change	2.97%

May-22-25 07:30AM	Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile) -8.17%
Apr-28-25 07:30AM	Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction (Newsfile)
Apr-21-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (Newsfile)
Mar-10-25 04:05PM	Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering (Newsfile) +11.48% -23.24%
Mar-06-25 08:30PM	Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering (Newsfile)
07:30AM	Loading…
07:30AM	Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (Newsfile)
Feb-27-25 07:30AM	Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) (GlobeNewswire) +12.16%
Feb-14-25 07:30AM	Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) (GlobeNewswire) +19.48%
Feb-11-25 07:41AM	Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV) (Newsfile)
Dec-12-24 07:30AM	Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch (GlobeNewswire)
Dec-02-24 07:30AM	Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region (GlobeNewswire) -8.72%
Nov-18-24 07:30AM	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer (Newsfile) -6.70%
Nov-15-24 04:47PM	Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States (Newsfile) -15.47%

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VELOCITY FUND PARTNERS, LP	10% Owner	May 20 '25	Sale	7.72	75,000	578,940	3,248,741	May 21 12:57 PM
VELOCITY FUND PARTNERS, LP	Major Shareholders	May 20 '25	Proposed Sale	195.49	118,000	23,067,500		May 20 03:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Medicus Pharma Ltd

Upgrade your FINVIZ experience